Sort
40,608 grants matching “prostate cancer”
Phosphodiesterase 10A, a novel target for lung cancer chemoprevention
$346,556Gary A Piazza · University Of South Alabama · R01 · FY2016 · CA
Phosphodiesterase 10A, a novel target for lung cancer chemoprevention
$346,556Gary A Piazza · University Of South Alabama · R01 · FY2017 · CA
The B7x pathway in the tumor microenvironment
$346,525Xingxing Zang · Albert Einstein College Of Medicine · R01 · FY2014 · CA
Role of Id1 in NSCLC Progression and Metastasis
$346,525Srikumar P Chellappan · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2009 · CA
The B7x pathway in the tumor microenvironment
$346,525Xingxing Zang · Albert Einstein College Of Medicine, Inc · R01 · FY2016 · CA
STAT1 Activation and HPP1 Tumor Suppression
$346,525David Shibata · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2010 · CA
The B7x pathway in the tumor microenvironment
$346,525Xingxing Zang · Albert Einstein College Of Medicine, Inc · R01 · FY2017 · CA
CANCER AND LEUKEMIA GROUP B
$346,521Sloan-Kettering Institute For Cancer Res · U10 · FY2003 · CA
Administrative Core
$346,513Phuoc T. Tran · University Of Maryland Baltimore · U54 · FY2023 · CA
Animal Core
$346,513Evan Todd Keller · University Of Michigan At Ann Arbor · P01 · FY2010 · CA
Surgical Studies of Functional Gene Expression
$346,510Bernard Mark Evers · University Of Texas Med Br Galveston · R01 · FY2006 · DK
Anticarcinogenic Effect of ITCs Against Prostate Cancer
$346,500Shivendra Singh · University Of Pittsburgh At Pittsburgh · R01 · FY2017 · CA
Anticarcinogenic Effect of ITCs Against Prostate Cancer
$346,500Shivendra Singh · University Of Pittsburgh At Pittsburgh · R01 · FY2018 · CA
Anticarcinogenic Effect of ITCs Against Prostate Cancer
$346,500Shivendra Singh · University Of Pittsburgh At Pittsburgh · R01 · FY2015 · CA
Anticarcinogenic Effect of ITCs Against Prostate Cancer
$346,500Shivendra Singh · University Of Pittsburgh At Pittsburgh · R01 · FY2016 · CA
THE CRUCIAL ROLE OF SCF SKP2 E3 LIGASE IN PROSTATE CANCER PROGRESSION AND METASTASIS
$346,500The Univeristy Of Texas M.D. Anderson Cancer Center · · FY2009 · Department of the Army
Improving chemotherapy of castration-resistant prostate cancer.
$346,488Xiaoqi Liu · University Of Kentucky · R01 · FY2021 · CA
CROSSTALK BETWEEN NOTCH SIGNALING AND LINEAGEDETERMINING TRANSCRIPTIONAL FACTORS DRIVES NEUROENDOCRINE DIFFERENTIATION IN ADVANCED PROSTATE CANCER
$346,460Dana-Farber Cancer Institute, Inc. · · FY2020 · Department of the Army
Project 3: Towards Understanding Prostate Cancer Heterogeneity
$346,460Mark A. Rubin · Weill Medical Coll Of Cornell Univ · P50 · FY2021 · CA
Project 3: Towards Understanding Prostate Cancer Heterogeneity
$346,459Mark A. Rubin · Weill Medical Coll Of Cornell Univ · P50 · FY2019 · CA
Intervention for Colorectal Cancer
$346,426Northwestern University · R01 · FY2002 · CA
Molecular biomarkers of selenium chemoprevention
$346,382Roswell Park Cancer Institute Corp · R01 · FY2002 · CA
CYCLIN D1 FUNCTION IN PROSTATE CANCER
$346,366Georgetown University · R01 · FY2003 · CA
Defining the role of isoprenylated xanthones from the mangosteen for enhancing degradation of full length and variant forms of androgen receptor in prostate cancer
$346,361Jeremy James Johnson · University Of Illinois At Chicago · R37 · FY2023 · CA
Influence of bone microenvironment on drug resistance in prostate cancer bone metastasis
$346,350Xiaohong Li · University Of Toledo Health Sci Campus · R01 · FY2023 · CA